What is Evolus's gross profit margin?

What is Evolus's latest dividend and current dividend yield?

What were the key takeaways from Evolus’s earnings call?

Did Evolus beat or miss consensus estimates last quarter?

What guidance did Evolus's management provide for the next earnings period?

What factors drove the changes in Evolus's revenue and profit?

What is the revenue and EPS growth rate for Evolus year over year?

What does Evolus do and what are its main business segments?

- **Revenue Resilience**: 12% full-year growth (14% Q4) despite U.S. market decline, driven by Jeuveau (14% share) and Evolysse (3,000+ accounts). 
- **Innovation Momentum**: Evolysse Q4 revenue $7.2M; Sculpt FDA approval Q4 2026. Portfolio rebates boost multi-product adoption. 
- **2026 Targets**: $327-337M revenue, 13-15% EBITDA margin by 2028, with 0-3% expense growth. 
- **Strategic Moves**: Co-branded media campaigns, clinic-specific marketing, and $30M credit facility for Sculpt launch. 
- **Risks & Opportunities**: Competing with new toxins; European market showing resilience (UK toxin share 10%). 


**【CEO Summary Section】**
- **Strategic Growth**: Delivered 12% full-year revenue growth (14% Q4) despite U.S. aesthetic market decline, driven by Jeuveau (14% U.S. market share) and Evolysse (3,000+ accounts). International revenue doubled year-over-year, now 8% of total. 
- **Product Innovation**: Launched Evolysse with Codex technology, achieving 7.2M in Q4; Sculpt FDA approval expected Q4 2026. Introduced portfolio growth rebates to incentivize multi-product adoption. 
- **2026 Outlook**: Target $327-337M revenue (10-13% growth), 13-15% EBITDA margin by 2028, with modest 0-3% non-GAAP expense growth. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Global net revenue $90.3M (+14% YoY), gross margin 67% (adjusted). Non-GAAP operating income $7.1M, up 6% YoY. 
- **2026 Guidance**: Revenue $327-337M, gross margin 65.5-67%, non-GAAP expenses $210-216M. Full-year profitability expected with low-mid single-digit EBITDA margin. 
- **Liquidity**: $53.8M cash, $30M revolving credit facility, and $100M long-term debt access. 

**【Q&A Highlights】**
- **Evolysse Adoption**: 3,000+ accounts, 7.2M in Q4. Sampling/training program to expand reach pre-Sculpt launch. Clinicians praise Codex efficiency and natural results. 
- **Marketing Strategy**: Co-branded media (e.g., Ipsy partnership), digital ads, and clinic-specific campaigns. 2026 media spend ~$7.5-9M. 
- **Competition**: Anticipate AbbVie (BoNT/E) and Galderma (liquid toxin) launches. Evolus' rebate program and differentiated portfolio position to defend share. 
- **Market Trends**: U.S. filler market decline moderating; Europe showing resilience (UK toxin share approaching 10%). 
- **Sculpt Impact**: 2027 launch expected to accelerate filler growth, with Sculpt对标 premium HA products. 
- **Inventory Dynamics**: Clinics remain cautious, but improving demand signals potential normalization. 


Evolus, Inc.(EOLS)-20260304-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 net revenue up 13% YoY to $69 million, driven by 14% U.S. Jeuveau market share and Evolysse's $5.7 million contribution.
- **Evolysse Breakthrough**: 75% of Evolysse revenue from accounts with second training, showing 100% purchase increase. Sequential growth of ~$5 million after launch stocking, with Sculpt PMA targeting mid-2026.
- **Profitability Path**: Q4 2025 target for first profitable quarter, with 2026+ sustainable annual profitability. Non-GAAP operating loss narrowed to $3.1 million (vs. $6.7 million YoY).
- **Tariff Mitigation**: Inventory stockpiling to avoid near-term Jeuveau tariff impact. Evolysse Europe tariff minimal, with U.S. supply chain unaffected.
- **Strategic Bundling**: Q4 portfolio bundle launch to test synergies between Jeuveau and Evolysse, with 2,000 adopters now purchasing both products.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 net revenue of $69 million, up 13% YoY, driven by strong global Jeuveau demand and Evolysse contributions ($5.7 million). Jeuveau sales grew 14% of U.S. market share, outperforming the declining aesthetic market.
- **Evolysse Momentum**: Evolysse revenue reached $15.5 million since launch, with 4,000 trained accounts and 2,000 adopters. 75% of Evolysse revenue comes from accounts with second training, showing 100% purchase increase post-second training. Q3 sequential growth of ~$5 million after launch stocking.
- **Strategic Initiatives**: Introduced first portfolio bundle in Q4 to align incentives across Jeuveau and Evolysse. Expanded customer base by 500 in Q3, total 17,000 accounts (2,000 now purchasing Evolysse). Evolus Rewards program saw 244,000 redemptions (68% repeat consumers).
- **Pipeline Progress**: Submitted FDA PMA for Evolysse Sculpt, targeting mid-2026 approval. Europe launch planned for H1 2026. Mitigating tariffs by stockpiling inventory ahead of potential U.S. pharmaceutical tariffs.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q3 2025 net revenue $69 million (13% YoY). Adjusted gross margin 67.6%. Non-GAAP operating loss $3.1 million (vs. $6.7 million YoY). Full-year 2025 guidance: $295-305 million revenue, $5-7 million Q4 non-GAAP operating income.
- **Expense Management**: Sequential cost reduction from Q2 ($55.5M GAAP OpEx) to Q3 ($57.3M), excluding one-time $3.9M contingent royalty revaluation. Full-year non-GAAP OpEx guidance $208-213 million.
- **Cash Position**: $43.5 million cash (down from $61.7M Q2 due to tariff mitigation inventory purchases). Q4 2025 target: first profitable quarter, with 2026+ sustainable annual profitability.
- **Tariff Impact**: Jeuveau inventory sufficient until Q1 2026, avoiding near-term tariff impact. Evolysse subject to 15% EU tariff, minimal financial impact.

**【Q&A Key Highlights】**
- **Evolysse Adoption**: 75% of Evolysse revenue from accounts with second training. Sequential growth of ~$5 million after launch stocking. 100% purchase increase post-second training. Q4 bundle launch to test portfolio synergies.
- **Jeuveau Dynamics**: 14% U.S. market share, outperforming -single-digit aesthetic market. Q3 sequential growth despite seasonality, driven by consumer loyalty program and Allure partnership.
- **Tariff Strategy**: Stockpiling inventory to mitigate potential U.S. pharmaceutical tariffs. Korea trade agreement resolution pending, no disruption expected to supply chain.
- **Pipeline Potential**: Evolysse Sculpt PMA submission, targeting mid-2026 approval. Europe launch planned for H1 2026. Sculpt trial data shows statistical superiority vs. Restylane Lyft at 6 months (91% vs. 83% responder rates).

Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Q2 2025 revenue grew 4% to $69.4 million, with Evolysse contributing $9.7 million in first-quarter sales despite U.S. toxin market softness.
- **Margin Management**: Gross margin at 66.5% (non-GAAP), with H2 improvement expected as introductory Evolysse discounts unwind.
- **Cost Efficiency**: $25 million annualized cost savings through strategic cuts, targeting Q4 2025 profitability and 2026 annual breakeven.
- **Growth Drivers**: Evolysse on track for 10-12% full-year contribution, international expansion to 9 markets, and 2028 $700 million revenue target reaffirmed.
- **Market Challenges**: U.S. toxin procedural volumes down high single digits YoY, but Jeuveau maintains 14% market share with clinical data validation (JAMA study showing fastest onset, longest duration).

**【CEO Summary Section】**
- Global net revenue for Q2 2025 was $69.4 million, a 4% increase over Q2 2024, driven by the successful launch of Evolysse ($9.7 million in first-quarter revenue) and international growth.
- Jeuveau units declined 15% YoY due to broader U.S. toxin market softness, but maintained 14% market share through Q2.
- Gross margin was 65.3% (GAAP) and 66.5% (non-GAAP), impacted by international pricing and introductory Evolysse discounts, with expectations for margin improvement in H2.
- Operating expenses were reduced by $25 million annually through strategic cost cuts (70% non-customer-facing), targeting Q4 2025 profitability.
- 2025 guidance updated to $295-305 million (11-15% growth), with Evolysse contributing 10-12% of total revenue.
- Long-term 2028 targets remain at $700 million revenue and 20% non-GAAP operating margin, supported by toxin market share gains and filler expansion.

**【CFO Financial Commentary】**
- Q2 GAAP operating loss was $7.9 million, with non-GAAP expenses at $54 million, reflecting $25 million annualized cost savings.
- Cash balance of $61.7 million at quarter-end, with strategic inventory purchases ahead of EU tariffs.
- Evolysse sourced from France will face 15% tariffs, but minimal impact on margins.

**【Q&A Key Highlights】**
- **Demand Dynamics**: U.S. toxin market procedural volumes down high single digits YoY, with Jeuveau outperforming market (-2% vs. -5%). Last 2 weeks of Q2 saw sharp order declines due to macro uncertainty, but July showed incremental improvement.
- **Evolysse Launch**: 50-50 mix of stocking and pull-through in Q2, with strong reorder rates and 1,000+ accounts trialing.
- **Competitive Landscape**: Hugel sampling minimal impact, no significant price changes, but consumer sentiment driving cautious spending.
- **Tariff Impact**: No immediate threat to Jeuveau (pharmaceutical exemption), but monitoring for broader market effects.
- **2025 Outlook**: H2 sequential improvement expected (14-18% growth), driven by Evolysse scale and market stabilization.
- **Strategic Moves**: Digital engagement (Evolus Rewards redemptions +65%), international expansion (9 markets, 70% TAM), and automation/AI investments to enhance productivity.

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

- **Revenue Growth & Share Leadership**: 15.5% YoY revenue growth to $68.5M, driven by 14% US market share and 70% reorder rate. Evolysse launch exceeds expectations with 2,000 early samples and 2,000+ trained clinicians.
- **Evolysse Momentum**: 8-10% of 2025 revenue from Evolysse, targeting $700M by 2028 with 20% operating margin. "Drop the F Word" campaign reframes HA as natural, resonating with consumers.
- **Financial Strength**: Non-GAAP EPS $1.08, 68.1% gross margin. Debt refinancing reduces costs by 350bps, providing $100M incremental capacity. Tariff impact <$2M annually.
- **Market Resilience**: Toxin market outperforms filler segment, with 1% share gain worth $20M annually. International growth outpaces US, supporting 30%+ YoY guidance.

**【CEO Summary Section】**
- **Revenue Growth & Market Share**: Q1 revenue of $68.5 million (+15.5% YoY), driven by 14% market share in the US (up 1% YoY). Outperformed a slower filler market with 70% reorder rate and 220,000 loyalty program redemptions.
- **Evolysse Launch Success**: Launched Evolysse Form & Smooth in April, exceeding expectations with 2,000 early samples, 2,000+ clinicians trained, and 20% of webcast attendees new to Evolysse. "Drop the F Word" campaign reframed HA as natural, aligning with consumer sentiment.
- **Strategic Expansion**: Projected 8-10% Evolysse contribution to 2025 revenue ($345-355M total), reaffirming 30%+ YoY growth. International toxin growth outpaces US, with 16,000+ accounts (30,000 total addressable).
- **Long-Term Vision**: Target $700M revenue and 20% non-GAAP operating margin by 2028, leveraging multi-product portfolio and disciplined cost management.

**【CFO Financial Commentary】**
- **Financial Performance**: GAAP net income $420M, Non-GAAP EPS $1.08 (vs. $0.95 prior). Gross margin 68.1% (69.2% adj.), operating expenses $61.8M (+12.6% YoY) due to Evolysse launch investments.
- **Tariff Mitigation**: 10% tariff on Evolysse (rising to 20% in July) estimated at <$2M annual impact. Proactive inventory management and P&L flexibility to absorb costs.
- **Debt Refinancing**: $250M facility with 350bps rate reduction, bullet maturity in 2030, and $100M incremental capacity. No prepayment fees, cost-effective at 1% of drawn value.
- **Profitability Outlook**: Non-GAAP operating income expected in Q4 2025, supported by $345-355M revenue and $230-240M operating expenses.

**【Q&A Key Highlights】**
- **Market Dynamics**: Filler market contraction due to macroeconomic trends and negative "filler" sentiment, offset by HA reframing. Toxin market resilient, with 1% share gain worth $20M annually.
- **Evolysse Adoption**: Early adopters include 99% of existing accounts and 20% new clinicians. Social media engagement surpasses recent competitor launches. No tariff-related inventory hoarding observed.
- **Competitive Strategy**: Evolysse pricing aligns with market leaders, with loyalty program benefits for combined Jeuveau/Evolysse purchasers. 2026 potential halo effect from Evolysse to Jeuveau adoption.
- **Tariff Clarification**: Evolysse classified as pharmaceutical, exempt from tariffs. Monitoring regulatory developments for mitigation strategies.

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

- **Revenue Growth Record**: 32% YoY to $266.3M, first profitable year 1 year ahead of plan.
- **Evolysse Breakthrough**: FDA-approved HA gels with Cold-X tech, targeting 78% market expansion. 2025 launch with 8-10% revenue contribution.
- **Market Leadership**: 14% U.S. share, 15,000+ accounts, 1.1M loyalty users. 2028 $700M+ target with 20%+ margins.
- **Financial Strength**: $87M cash, 13% expense growth vs. 32% revenue. Q1 2025 cash use expected for Evolysse ramp-up.
- **Innovation Edge**: Unique weight loss label, superior clinical performance, and co-branded media benefits driving differentiation.

**【CEO Summary Section】**
- **Record Year Achievements**: 2024 revenue grew 32% to $266.3 million, surpassing top-end guidance. Full-year profitability was achieved 1 year ahead of target, with U.S. market share approaching 14%.
- **Product Milestones**: FDA approval for Evolysse Form and Smooth in Q2 2025, expanding total addressable market by 78%. 2025 revenue guidance set at $345M-$355M, maintaining 30%+ growth.
- **Strategic Expansion**: Added 2,900 new accounts (total 15,000+), 1.1M Evolus Rewards users (+40%), and international expansion to Australia, Spain, and U.K. with $100M+ 2028 target.
- **Evolysse Launch Plan**: Q2 2025 rollout with training, sampling, and co-branded media benefits. Pricing aligned with leading HAs, with 99% Jeuveau customers expressing interest.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Revenue $79M (+30% YoY), non-GAAP operating income $6.7M (vs. $3.7M loss in 2023 Q4). Full-year non-GAAP operating income $13.8M, marking first profitable year.
- **Gross Margin Stability**: Adjusted gross margin 67.5% (Q4) and 69.6% (full year), consistent with prior year. Operating expenses grew 13% vs. 32% revenue growth, demonstrating leverage.
- **Cash Position**: $87M at end of Q4, up from $85M. Anticipate Q1 2025 cash use due to seasonality and Evolysse launch ramp-up.
- **Long-Term Outlook**: Target $700M+ revenue by 2028 (+27% CAGR) with 20%+ non-GAAP operating margin, driven by HA portfolio and efficient cash-pay model.

**【CMO Product Innovation】**
- **Evolysse Technology**: Cold-X process preserves HA structure, resulting in superior shear/compression resistance. Evolysse Form and Smooth demonstrated statistical superiority vs. Restylane in clinical trials.
- **Unique Labeling**: First HA to mention weight loss as cause of wrinkles, positioning for GLP-1 patient growth. Evolysse Smooth approved for perioral fine lines, Evolysse Form for nasolabial folds/marionette lines.
- **Clinical Performance**: Evolysse Form showed statistical significance at all time points, Evolysse Smooth at 6-9 months. Label includes 95% confidence intervals and p<0.001, highlighting superiority.

**【Q&A Key Takeaways】**
- **Market Dynamics**: U.S. toxin market growing high-single digits, filler market stabilizing post-COVID. Evolysse's weight loss label and Cold-X tech differentiate in competitive HA space.
- **Subscription Model**: Club Evolus pilot shows strong interest, with 100+ early adopters. Full launch planned for 2025, targeting patient retention and upselling.
- **International Growth**: 5% of 2024 revenue from international, targeting $100M+ by 2028. Australia and Spain launches performing well, U.K. at U.S. 2-year market share levels.
- **Competitive Position**: 14% U.S. share vs. 50% addressable market. Evolysse gives access to filler market, complementing Jeuveau's toxin leadership.

Actual										-0.7533	-0.4383	-0.2741	-0.4402	-0.3414	-0.1929	-0.2628	-0.2255	-0.2167	-0.3265	-0.2778	-0.1367	-0.1512	-0.1953	-0.1648	-0.1245	-0.0828	-0.0395	-0.1617	0.0327	-0.1486	-0.2467	-0.1322	0.0442
Forecast										-0.64	-0.7488	-0.3988	-0.2613	-0.465	-0.26	-0.2714	-0.2243	-0.3414	-0.2616	-0.3075	-0.1679	-0.1863	-0.2529	-0.2225	-0.072	-0.1519	-0.0525	-0.1233	0.02	-0.141	-0.0986	-0.1629	0.0301
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-17.70%	+41.47%	+31.27%	-68.47%	+26.58%	+25.81%	+3.17%	-0.53%	+36.53%	-24.81%	+9.66%	+18.58%	+18.84%	+22.78%	+25.93%	-72.92%	+45.49%	+24.76%	-31.14%	+63.50%	-5.39%	-150.20%	+18.85%	+46.84%

EOLS

EOLS fundamentals

EOLS Q4 2025 Earnings

Earnings Call

You can ask Aime

EOLS

EOLS fundamentals

EOLS Q4 2025 Earnings

Earnings Call

EOLS Earnings Call Summary for Q4/20254:30 PM on Mar 3, 2026

EOLS Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

EOLS Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

EOLS Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

EOLS Earnings Call Summary for Q4/20244:30 PM on Mar 4, 2025

You can ask Aime